A Phase 3, Randomised, Parallel-group, Active-controlled, Double-blind Study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Celltrion; PPD
- 25 Apr 2016 Planned number of patients changed from 104 to 174.
- 25 Apr 2016 Planned End Date changed from 1 Aug 2020 to 1 Mar 2020.
- 25 Apr 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Aug 2018.